Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: "Christie M. Ballantyne" Clear advanced filters

  • Accumulation of foam cells — macrophages with intracellular lipid droplets — in arterial walls is a hallmark of atherosclerosis. Bernelot Moens and colleagues report increases in circulating monocytes with intracellular lipid accumulation, associated CCR2 expression, and enhanced monocyte migration in patients with familial hypercholesterolaemia. These changes could be reversed by PCSK9-inhibitor treatment.

    • Huaizhu Wu
    • Christie M. Ballantyne
    News & Views
    Nature Reviews Cardiology
    Volume: 14, P: 385-386

  • The relationship between an elevated level of LDL cholesterol (LDL-C) and increased risk of cardiovascular disease is well established. National and international guidelines are continuously being revised to recommend increasingly lower LDL-C targets for cardiovascular disease prevention. In this Review, Drs. Brautbar and Ballantyne examine the evidence and recommendations for optimal LDL-C levels and the agents currently available or under development to achieve these levels.

    • Ariel Brautbar
    • Christie M. Ballantyne
    Reviews
    Nature Reviews Cardiology
    Volume: 8, P: 253-265

  • Statins and other drugs are widely used to lower the LDL-cholesterol level, which has been shown to prevent cardiovascular events. In this Review, Dadu and Ballantyne review the latest evidence on a novel class of LDL-lowering agents: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In particular, monoclonal antibodies against PCSK9 have proven efficacious and safe in phase I–III clinical trials.

    • Razvan T. Dadu
    • Christie M. Ballantyne
    Reviews
    Nature Reviews Cardiology
    Volume: 11, P: 563-575